Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Cureus|May 14, 2025
Lactate-to-Albumin Ratio (LAR) as a Predictor of All-Cause Mortality in Patients With Myocardial Infarction: A Systematic Review and Meta-AnalysisMujahed Ul Islam, Uday Gollapinni, Shabab Ul Hassan, et al.
Cureus|April 22, 2024
Comparison of the Effectiveness and Safety of Metoprolol and Diltiazem in Atrial Fibrillation With Rapid Ventricular Rate Patients: A Systematic Review and Meta-AnalysisAbshiro H Mayow, Tanya Sinha, Mansoor Ahmad, et al.
Cureus|April 15, 2025
Efficacy of Tislelizumab in Lung Cancer Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsWaqas Ul Bassar, Oboseh J Ogedegbe, Asfia Qammar, et al.
Cureus|October 7, 2024
Comparison of Efficacy of Atorvastatin and Rosuvastatin in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-AnalysisDarab Shuja, Muhammad Umar Mian, Manpreet Kaur Dhanjal, et al.
Cureus|February 24, 2025
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio on Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-AnalysisAnurag Rawat, Priya Goyal, Syed Ali Ahsan, et al.
Cureus|August 11, 2022
Efficacy and Safety of Colchicine in Prevention of Secondary Cardiovascular Outcomes Among Patients With Coronary Vessel Disease: A Meta-AnalysisLubna Sattar, Rahat A Memon, Fatima Ashfaq, et al.
Journal of Infection in Developing Countries|May 10, 2024
Drug repurposing: identification of SARS-CoV-2 potential inhibitors by virtual screening and pharmacokinetics strategiesZubia Rashid, Amal Fatima, Areeba Khan, et al.
Blood Advances|August 31, 2022
Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AMLMohammad Azhar, Zachary Kincaid, Meenu Kesarwani, et al.
International Journal of Biological Macromolecules|August 22, 2024
Revitalizing antimicrobial strategies: paromomycin and dicoumarol repurposed as potent inhibitors of M.tb's replication machinery via targeting the vital protein DnaNWaseem Ali, Meetu Agarwal, Salma Jamal, et al.
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
A novel hyperactive BCR::ABL1 e6a3 variant confers resistance to combined asciminib plus ponatinib therapyValentina Nardi, Joshua Schwieterman, Sekhu Ansari, et al.
Pageof 6